Active Biotech AB
12
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
90.9%
+4.4% vs industry average
8%
1 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Role: collaborator
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Role: collaborator
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Role: collaborator
A Study of Laquinimod Eye-drops in Healthy Participants
Role: lead
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Role: lead
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Role: lead
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Role: lead
Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
Role: lead
An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
Role: lead
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
Role: lead
A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects
Role: lead
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Role: lead
All 12 trials loaded